LUNG Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -64.91% compared to Pulmonx Corp.'s net margin of 12.65%. Pulmonx Corp.'s return on equity of -73.42% beat Electromed, Inc.'s return on equity of 18.89%.

Pulmonx Corp. has a consensus price target of $5.75, signalling upside risk potential of 186.07%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Pulmonx Corp. has higher upside potential than Electromed, Inc., analysts believe Pulmonx Corp. is more attractive than Electromed, Inc..

Pulmonx Corp. has a beta of 0.219, which suggesting that the stock is 78.135% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $21.5M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Pulmonx Corp.'s net income of -$14M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.88x versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -64.91% compared to Pulmonx Corp.'s net margin of -12.6%. Pulmonx Corp.'s return on equity of -73.42% beat IRIDEX Corp.'s return on equity of -155.93%.

Pulmonx Corp. has a consensus price target of $5.75, signalling upside risk potential of 186.07%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 112.7%. Given that Pulmonx Corp. has higher upside potential than IRIDEX Corp., analysts believe Pulmonx Corp. is more attractive than IRIDEX Corp..

Pulmonx Corp. has a beta of 0.219, which suggesting that the stock is 78.135% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $21.5M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. Pulmonx Corp.'s net income of -$14M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.88x versus 0.31x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -64.91% compared to Pulmonx Corp.'s net margin of -36.3%. Pulmonx Corp.'s return on equity of -73.42% beat Myomo, Inc.'s return on equity of -68.35%.

Pulmonx Corp. has a consensus price target of $5.75, signalling upside risk potential of 186.07%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 380.77%. Given that Myomo, Inc. has higher upside potential than Pulmonx Corp., analysts believe Myomo, Inc. is more attractive than Pulmonx Corp..

Pulmonx Corp. has a beta of 0.219, which suggesting that the stock is 78.135% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $21.5M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Pulmonx Corp.'s net income of -$14M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.88x versus 1.02x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of -64.91% compared to Pulmonx Corp.'s net margin of -86.59%. Pulmonx Corp.'s return on equity of -73.42% beat Stereotaxis, Inc.'s return on equity of -218.3%.

Pulmonx Corp. has a consensus price target of $5.75, signalling upside risk potential of 186.07%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 76.35%. Given that Pulmonx Corp. has higher upside potential than Stereotaxis, Inc., analysts believe Pulmonx Corp. is more attractive than Stereotaxis, Inc..

Pulmonx Corp. has a beta of 0.219, which suggesting that the stock is 78.135% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $21.5M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. Pulmonx Corp.'s net income of -$14M is lower than Stereotaxis, Inc.'s net income of -$6.5M. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.88x versus 7.10x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.